ATTO (Attovia Therapeutics) NonCurrent Deferred Revenue: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.70
View Full Analysis

What is Attovia Therapeutics NonCurrent Deferred Revenue?

Attovia Therapeutics ATTO -6.94% 8 NonCurrent Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Attovia Therapeutics's non-current deferred revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

Attovia Therapeutics NonCurrent Deferred Revenue Related Terms

Attovia Therapeutics NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics NonCurrent Deferred Revenue Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
NonCurrent Deferred Revenue
0.00 0.00

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
NonCurrent Deferred Revenue 0.00 0.00 0.00 0.00
ATTO
8GF Score
Attovia Therapeutics Inc ATTO
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Attovia Therapeutics (ATTO) has a NonCurrent Deferred Revenue of $0.00 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Attovia Therapeutics and its competitors.
Is Attovia Therapeutics' NonCurrent Deferred Revenue too high?
Attovia Therapeutics' current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' NonCurrent Deferred Revenue compare to ?
Attovia Therapeutics' NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Attovia Therapeutics and its competitors. Attovia Therapeutics's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current NonCurrent Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.70
Price